Objective: To explore the therapeutic potential of endothelial progenitor cells (EPCs) transfected with vascular endothelial growth factor A (VEGFA) and heme oxygenase-1 (HO-1) on rat hindlimb ischemia model. Methods: Eukaryotic expression vectors encoding VEGFA or HO-1 were constructed and introduced into EPCs isolated from rat bone marrow. In total, 150 Sprague Dawley rat hindlimb ischemia models were established and randomized into five groups which were injected via tail vein with phosphate-buffered saline (PBS), nontransfected EPCs, VEGFAmodified EPCs, HO-1-modified EPCs, and both VEGFA-and HO-1-modified EPCs, respectively. The microvessel density, the expressions of VEGFA and HO-1 in the ischemic limbs, the recovery of blood flow as evaluated by laserDoppler perfusion imaging, and the rate of limb salvage were compared among different groups. Results: Transplantation of both VEGFA-and HO-1-modified EPCs in recipient rats significantly increased the microvessel density (expressed as capillaries/m 2 at day 21 after operation, group vascular endothelial growth factor (VEGF)DHO-1, 357 6 14.1; group VEGF, 253.7 6 9.9; group HO-1, 255.5 6 12.5; group EPC, 210.7 6 10.3; group PBS, 144.3 6 9.3; P < .001), the expressions of VEGFA and HO-1 in ischemic tissue, the recovery of blood flow (at day 21, VEGFDHO-1 group, 85.4 6 17.8%; VEGF group, 51.2 6 13.2%; HO-1 group, 50.4 6 12.9%; EPC group, 39.9 6 8.5%; PBS group, 28.3 6 7.8%; P < .001), and the rate of limb salvage (VEGFDHO-1 group, 94.4%; VEGF group or HO-1 group, 63.6%; EPC group, 50.0%; PBS group, 11.1%), compared with transplantation of either VEGFA-or HO-1-modified EPCs alone, or of nontransfected EPCs, or PBS injection. The order of therapeutic effectiveness on ischemic limbs was VEGFA-D HO-1-modifed EPC > either VEGFA-or HO-1-modified EPC alone > nontransfected EPC > PBS. Conclusions: VEGFA-modified EPC and HO-1-modified EPC synergized with each other in promoting angiogenesis in ischemic limbs of rat hindlimb ischemia model. In addition to VEGF, the introduction of HO-1 in EPC-based transplantation may serve as a novel and useful therapeutic strategy for ischemic disease of lower extremity. (J Vasc Surg 2013;58:756-65.) Clinical Relevance: Genetically modified endothelial progenitor cell (EPC) is useful in designing strategies to achieve dual purposes in treating peripheral arterial disease: targeted delivery of therapeutic genes using EPC as vehicle, and enhancement on the angiogenic properties of EPC by the expression of therapeutic genes. Heme oxygenase-1 (HO-1) has been shown to play an important role in ischemic angiogenesis, aside from its role as an antioxidant protein. We have shown for the first time that vascular endothelial growth factor A-modified EPC and HO-1-modified EPC synergized with each other in promoting angiogenesis in rat hindlimb ischemia model. These findings provide further evidence of the importance of both HO-1 and vascular endothelial growth factor in neovascularization.
The prevalence of peripheral arterial disease (PAD) affecting the lower extremities rises in line with an ageing population in China. Patients with continued progression of PAD will experience the end-stage critical limb ischemia (CLI) resulting in amputation of the affected limb and increased mortality. 1 Revascularization can be achieved either by endovascular interventions or open surgery combined with anticoagulation and antiplatelet agents. Unfortunately, a considerable proportion of patients are not eligible for these revascularization procedures because of the widespread nature, the distal location of the obstructions, or the presence of comorbidities. 2 For these patients, noninvasive revascularization strategies, mainly single gene/protein-based or cell-based, have been developed. Recently, a number of double-blind, randomized phase I/II trials have verified the safety and efficacy of local injection with bone marrow (BM) aspirate concentrate 3 or BM derived cells with 4 or without 5 in vitro expansion in patients with "no option" CLI. Though not powered to show statistical significance, these studies demonstrate favorable outcome for cell therapy vs control in amputation free survival, ankle brachial index, wound healing, improved Rutherford classification, and quality of life, indicating that autologous BM cell-based therapy is a safe and effective strategy to promote limb salvage in CLI patients. However, the exact mechanisms of action for these cells (a mixture of mesenchymal and hematopoietic progenitor cells and other cell types in BM) in treating CLI are not well established. It is unclear whether these cells are directly involved in angiogenesis or just providing cytokines. The adoption of a more purified cell population may be a better choice to illustrate part of the mechanism.
Endothelial progenitor cells (EPCs) are not only involved in embryonic vascularization, but also played an important role in adult organism angiogenesis. 6 Reduced circulating EPC number or function indicates an impaired endothelial repair capacity resulting in increased risk of vascular disease. 7, 8 Infusion of ex vivo expanded EPC derived from BM or peripheral blood was shown to augment capillary density and neovascularization of ischemic tissue in animal models. 9 Therefore, EPC may become a promising cell type to treat limb ischemia. 10 The role of vascular endothelial growth factor (VEGF) in treating ischemic diseases was documented two decades ago. Isner and Losordo performed substantial preclinical studies on the safety and efficacy of direct intra-arterial or intramuscular transfer of naked DNA encoding human VEGF in treating PAD in animal models and in human subjects. Their pioneering work demonstrated that VEGF gene transfer could increase circulating EPC, augment angiogenesis after ischemia, and accelerate endothelial recovery after injury, providing a solid basis for further research of therapeutic angiogenesis using VEGF genebased strategies. 11, 12 In recent years, the important role of heme oxygenase-1 (HO-1) in postnatal angiogenesis was gradually recognized. 13 HO-1 is an enzyme that catalyzes the first, rate-limiting step in degradation of heme into carbon monoxide (CO), ferrous iron, and biliverdin. Known to have cytoprotective, proangiogenic, and antiapoptotic properties, these three smaller compounds, together with HO-1 itself, are claimed to be the second, after glutathione, most important part of the anti-oxidative protection system. 13, 14 Recent data provided powerful evidence for the involvement of HO-1 in therapeutic angiogenesis, making HO-1-based gene or cell therapy a promising strategy to treat ischemic diseases. 15 Furthermore, HO-1 was reported to form a positive feed-back loop with VEGF. 16 Grochot-Przeczek et al recently discovered that HO-1 functioned both upstream and downstream of VEGF, inducing its expression and being required for the proper response of EPC to VEGF stimulation. 17 We hypothesize that the application of both HO-1-and VEGF-based therapies to ischemic disease model at the same time may lead to more effective angiogenesis.
In our previous study, we reported that local application of stromal-derived factor-1a synergized with vascular endothelial growth factor A (VEGFA)-modified EPC in therapeutic angiogenesis by enhancing EPC migration, reducing EPC apoptosis, and increasing capillary density and blood flow recovery. 18 In this study, we transplant EPC overexpressing either HO-1 or VEGFA into rat hindlimb ischemia model and investigate whether HO-1 and VEGFA can synergize with each other in facilitating angiogenesis.
METHODS
Mouse EPC isolation and culture. Male SpragueDawley rats were provided by Laboratory Animal Centre of Sun Yat-sen University. All researches involving animals were approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University. Bone marrow mononuclear cells were isolated from Sprague-Dawley rat bones as described previously, 19 cultured in endothelial cell basal medium-2 (Clonetics; Lonza, Walkersville, Md) supplemented with 20% fetal bovine serum, human VEGF, fibroblast growth factor 2, epidermal growth factor, insulin-like growth factor-1, ascorbic acid, and antibiotics. All growth factors were purchased from Peprotech, Rocky Hill, NJ. After 4 days of culture, nonadherent cells were removed, fresh medium was applied, and the culture was maintained through day 7.
20 Cells at passage 3 (P3) were cultured for later experiments.
Construction of VEGF and HO-1 expression vectors and gene transfer into EPC. VEGFA and HO-1 genes were amplified by polymerase chain reaction using DNAs extracted from Sprague-Dawley rat aorta and spleen as templates, respectively. Primers for VEGFA (NM-031836): up-stream: 5 0 -GACGGATCCATGAACTTTC TGCTCTCTTGGGTGC-3 0 , down-stream: 5 0 -TGAAAGC TTTCACCGCCTTGGCTTGTCAC-3 0 ; and HO-1 (NM-012580): up-stream: 5 0 -CGGGATCCATGGAGCGCCCA CAGCTCGAC-3 0 , down-stream: 5 0 -CCCAAGCTTTTAC ATGGCATAAATTCC CAC-3 0 were used. The polymerase chain reaction products were digested with bamHI and hindIII (Invitrogen, Carlsbad, Calif), and cloned into a pCMV-Tag 2B expression vector that was provided by Dr Anlong Xu in Life Science College of Sun Yat-sen University. pCMV-Tag 2B/VEGFA or pCMV-Tag 2B/HO-1 were transfected into the EPCs using lipofectamine 2000 (Invitrogen). The pEGFP (Clontech, Mountain View, Calif) was cotransfected as an internal control for transfection efficiency. Western blotting detections of VEGF-R2, VEGF, and HO-1 proteins were performed as described in the Supplementary Methods section (online only).
RNA extraction and real-time quantitative polymerase chain reaction. A detailed description is available in the Supplementary Methods section (online only). The following oligonucleotide primers were used: rat b-actin: 
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Quantification was processed using Q-Gene software (free web access to this program is available at http:// www.biotechniques.com/softlib/qgene.html).
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Identification of rat BM-derived EPC. P3 EPCs were subjected to 1,1-dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine-labeled acetylated low-density lipoprotein (Dil-Ac-LDL) and fluorescein isothiocyanatelabeled lectin from Ulex europaeus agglutinin I (FITC-UEA-1-lectin) double staining 25 and flow cytometry analysis for CD34 and CD133 surface markers. EPCs crawling microscopic slides of logarithmic growth were subjected to immunohistochemical (IHC) staining for CD34, CD133, and Von Willebrand factor (vWF). A detailed description is available in the Supplementary Methods section (online only).
EPC transplantation animal model. Male SpragueDawley rats, 8-9 weeks' old, weighing 180-200 g, were intraperitoneally anesthetized with sodium pentobarbital (160 mg/kg) for operative resection of the femoral artery in one of the hindlimbs, as described briefly in the Supplementary Methods section (online only). In total, 150 animals were randomized into five groups according to transplantation regime received through tail vein after surgery: phosphate-buffered saline (PBS) injection, transplantation of nontransfected EPC (EPC), pCMV-Tag 2B/VEGFA-transfected EPC (VEGF), pCMV-Tag 2B/ HO-1-transfected EPC (HO-1), and both pCMV-Tag 2B/VEGFA and pCMV-Tag 2B/HO-1-transfected EPC (VEGFþHO-1). Within each group, six animals were euthanized at days 7 and 14 to obtain ischemic tissue for quantitative polymerase chain reaction (Q-PCR), Western blotting, and microvessel density (MVD) measurement; the remaining 18 animals were scanned with laser Doppler imager (LDPI) and evaluated macroscopically for ischemic damage at days 7, 14, and 21. At day 21, six out of the 18 rats were euthanized for MVD measurement after LDPI scanning. Immediately after the operation, each animal was injected with 0.2 mL PBS in group PBS, 0.2 mL EPC cell suspension (5 Â 105 cells) in group EPC, 0.2 mL VEGFAmodified EPC (2.5 Â 105 cells) in group VEGF, 0.2 mL HO-1-modified EPC (2.5 Â 105 cells) in group HO-1, and 0.2 mL cell suspension containing both VEGFA-and HO-1-modified EPC (2.5 Â 105 cells per gene) in group VEGFþHO-1. Indicators such as expressions of VEGFA, HO-1, or MVD, perfusion, and salvage rate of ischemic limb were tested and compared among different groups.
In vitro labeling of EPCs with BrdU and IHC staining of BrdU in ischemic tissue. A measurement of 10 mL of the 1 mM BrdU (550891; BD Pharmingen, San Diego, Calif) working solution was added directly to each mL of tissue culture media, with cell density of 1 Â 106/mL. After incubation for 48 hours, cells were harvested and adjusted to a density of 2.5 Â 106/mL before injecting into the animals. Animals were sacrificed at days 7 and 14 after the operation. Paraffin-embedded sections of rat muscle tissue taken from the ischemic area were subjected to IHC staining for BrdU using BrdU in situ detection kit (551321, BD Pharmingen).
MVD measurement. Determination of the MVD was performed as previously described. 26 Briefly, after IHC staining for vWF in ischemic tissue specimens, each slide was first scanned under a low power objective lens to determine "hot spots" defined as areas with the maximum number of microvessels. The slides were then examined at Â400. Areas of staining with no discrete breaks were counted as a single vessel. Data were expressed as mean 6 standard deviation/mm 2 of 10 randomly selected nonoverlapping high-power fields.
Laser Doppler perfusion imaging assessment and ischemic damage assessment. LDPI (Lisca AB, Linkö-ping, Sweden) was used to record blood flow changes on days 7, 14, and 21 after surgery, as previously described. 18 Briefly, the animal was put in dorsal position after intraperitoneal anesthesia with its hindlimb slightly fixed and excess hairs removed before imaging. Room temperature was stabilized at 25 C. To account for variables including light and temperature, calculated perfusion was expressed as a ratio of surgical to nonsurgical limb. The degree of ischemic damage on the affected limb was evaluated once every 3 days macroscopically.
Statistical analysis. All results were expressed as mean 6 standard deviation. Statistical significance was evaluated using the paired t-test for comparisons between two means. Comparisons between multiple groups were done using ANOVA. All statistical analyses were performed using SPSS v. 17.0 (SPSS Inc, Chicago, Ill). A P value of .05 was considered statistically significant.
RESULTS

Identification of EPC cultured in vitro
Morphologic changes of EPC under microscope. Putative EPCs initially isolated (passage 1, P1) were small, round, and undistinguishable from blood cells. Some of the cells presented spindle shape with short protrusions at day 5, but did not display a uniform morphology. P2 cells were predominant in adhesive growth. A considerable proportion of cells changed to spindle shape with a tendency to form cluster or colony. P3 cells displayed uniformly spindle-shaped with long protrusions and a tendency to form lines ( Supplementary Fig 1, online only) .
IHC staining of adherent cells. CD133 and CD34 antigens are shared by both embryonic EPCs and hematopoietic stem cells. vWF is a multifunctional hemostatic glycoprotein derived from endothelial cells. Therefore, testing the expressions of these three markers helps to identify EPCs derived from BM. The expressions of CD133, CD34, and vWF were found mainly in the cytoplasm, as indicated by yellow or brown color. As shown in Fig 1, P3 cells appeared moderately positive for CD133 (Fig 1, A2) whereas weakly positive for both CD34 (Fig 1,  A3 ) and vWF (Fig 1, A4) in the absence of VEGF induction. After three generations of human VEGF induction, the expressions of CD34 and vWF dramatically increased (Fig 1, B3 and B4 ).
Flow cytometry analysis for surface biomarkers of EPCs. As shown in Fig 2, A, the percentage of cells positive for CD133 in P3 was (97.3% 6 1.5%), whereas that of CD34 in P3 was (55.5% 6 3.2%). After induction of VEGF, there was no significant change in the percentage of cells positive for CD133 (91.4% 6 1.2%), whereas the percentage of CD34þ cells increased to (78.6% 6 4.2%) (P < .01).
Dil-Ac-LDL and UEA-1-lectin double-staining detection of EPCs. The increased metabolism of acetylated low-density lipoprotein (Ac-LDL) in endothelial cells and the cytoplasmic affinity of Ulex europaeus agglutinin I (UEA-I) for capillary endothelium were put in good use to identify epithelial lineage differentiated from BM progenitor cells. In total, 20.4% 6 3.8% of P3 cells were positive for both Dil-Ac-LDL (red) and UEA-1-lectin (green) without the induction of VEGF (image not shown). The double positive cells increased to 70.2% 6 5.1% after induction by VEGF (Fig 2, B) .
Expression of VEGF-R2 in EPCs. Numerous studies reported that VEGF-R2 was one of the most important markers for the epithelial lineage. 6 As shown in Fig 2, C, VEGF-R2 messenger (mRNA) expression in P3 cells with VEGF induction was roughly two times as that in cells without induction (P < .01). Western blotting analysis also confirmed that VEGF induction increased the protein expression of VEGF-R2 in P3 cells, indicating that VEGF factor promoted the differentiation of epithelial lineage from multilineage progenitor cells.
Construction of VEGF and HO-1 genetically modified EPCs. EPCs transfected with pCMV-Tag 2B/ VEGFA or pCMV-Tag 2B/HO-1 were examined under fluorescence microscope. As shown in Fig 3, A, the transfection efficiency was roughly 80% for both genes 48 hours after transfection. The mRNA levels and protein expressions of VEGFA and HO-1 were detected. As shown in Fig 3, B, basal level of VEGFA and HO-1 were expressed in nontransfected EPCs, whereas robust expressions of either VEGFA or HO-1 in EPCs were observed after transfection (P < .001).
Efficiency of EPC transplantation rat model of hind limb ischemia
Incorporation of transplanted EPC in neovasculature. EPCs labeled with BrdU were injected into the animals right after surgery. BrdU IHC staining was performed at days 7 and 14 after operation. Transplanted EPCs were identified in tissue sections as brown cells forming lines ( Supplementary Fig 2, online only) , indicating such EPCs survived in the ischemic tissue and were successfully incorporated in the microvasculature of the ischemic limb.
Transgene expression after transplantation of genemodified EPCs. Expressions of mRNA and protein of VEGFA and HO-1 in ischemic tissue from the affected limb were detected with Q-PCR and Western blotting. VEGFA mRNA and protein expressions in groups VEGF and VEGFþHO-1 were significantly increased, compared with groups PBS, EPC, and HO-1 (P < .001), whereas no statistical difference was found between these two groups. Though less dramatic, a significant increase of VEGFA gene expression was found in group HO-1, compared with groups PBS and EPC (P < .05) (Fig 4, A, left panel) . Similarly, HO-1 mRNA and protein expressions in group HO-1 and VEGFþHO-1 were significantly increased, compared with groups PBS, EPC, and VEGF (P <.001), whereas there was no statistical difference between these two groups (Fig 4, A, right panel) . group were euthanized at 7, 14, and 21 days after operation. Skeletal muscle sections taken from the ischemic limb were subjected to IHC staining for vWF. Microvessels in 10 randomly selected high power (Â400) fields in each section were counted. MVD increased in each group in a timedependent manner (Table I, Fig 4, B, left panel) . At each time point, MVD in group EPC was statistically higher than that in group PBS (P < .05) but lower than that in groups VEGF, HO-1, or VEGFþHO-1 (P < .05). Meanwhile, no statistical difference in MVD was found between groups VEGF and HO-1 at any timepoint. Group VEGFþHO-1 did not show significantly increased MVD until day 14 after operation (295.5 6 12.1/m 2 vs 201.5 6 10.9/m 2 in VEGF and 216.3 6 11.3/m2 in HO-1; P < .001), and the difference remained statistically significant at day 21 (357 6 14.1/m 2 ), compared with groups VEGF (253.7 6 9.9/m 2 ) and HO-1 (255.5 6 12.5/m 2 ) (P < .001) (Fig 4, B, right panel) . Detection of blood flow by LDPI. Subcutaneous blood flow rate detected by LDPI is an objective indicator for blood flow perfusion. As shown in Fig 5, A and B and Table II , at day 7 after operation, the overall ratio of ischemic/normal blood flow decreased in all groups. Group VEGFþHO-1 showed the highest ratio of ischemic/normal blood flow at each time point, compared with other groups (P < .001), while no statistical difference was found between groups VEGF and HO-1 at any timepoint (Fig 5, A) . At day 21, perfusions of affected limbs in group VEGFþHO-1 (85.4% 6 17.8%) were comparable to limbs without surgery. Meanwhile, the degree of restoration of blood flow of affected limbs in groups VEGF (51.2% 6 13.2%) and HO-1 (50.4% 6 12.9%) was significantly higher than that in groups EPC (39.9% 6 8.5%) or PBS (28.3% 6 7.8%) (P < .05). The difference between group EPC and group PBS was also statistically significant at day 21 (P < .001).
Comparison of the degree of ischemia damage among five groups. The necrosis occurred as early as 10 days after operation. The position of necrosis (mainly toe, foot, or crus) was largely dependent on severity of ischemia Endothelial progenitor cell (EPC) biomarkers expression in P3 cells. P3 cells at the end of the 7-day culture were collected and subjected to EPC biomarkers testing. CD133 and CD34 expressions were quantified as the percentage of cells labeled by fluorescein isothiocyanate (FITC)-conjugated secondary antibodies, which were bound to primary antibodies against these two proteins, data were expressed as the (mean 6 standard deviation)% of triplicate readings of each sample in one experiment representative of three performed with similar results (A). At day 7, P3 cells intensively took up 1,1-dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine-labeled acetylated low-density lipoprotein (Dil-Ac-LDL) (red) and bound to an endothelial-specific lectin-FITC (green) as revealed by fluorescence microscopy (B). Quantitative analysis of the percentage of cells positive for Dil-Ac-LDL/lectin dual staining (merge) was performed as described in the Methods section. Total RNA from P3 cells were amplified by real-time polymerase chain reaction (RT-PCR) using specific vascular endothelial growth factor (VEGF)-R2 and b-actin primers. Data were expressed as the mean 6 standard deviation of three samples of each group in one experiment representative of three performed with similar results (C). Whole cell extracts were subjected to Western blotting, testing protein expression of VEGF-R2. The representative image of three independent experiments was shown. *P < .01 vs no human VEGF induction.
but not uniform even within the same group. Autodisarticulations of toe, foot, or the distal one-third of the crus from the affected limb were observed in all groups except group VEGFþHO-1, indicating transplantation of VEGFA-and HO-1-modified EPC prevented animals from progression to end-stage CLI. The order of necrosis severity among groups was PBS > EPC > either VEGF or HO-1 > VEGFþHO-1, and the order of limb salvage rate (11.1% in PBS, 50.0% in EPC, 63.6% in VEGF or HO-1, 94.4% in VEGFþHO-1) was the opposite (Table III; Fig 5, C) .
DISCUSSION
The results of this study show that transplantation of both VEGFA-and HO-1-modified EPC is superior to transplantation of either VEGFA-modified or HO-1-modified EPC alone in therapeutic revascularization in rat hindlimb ischemia model. Our results clearly demonstrate that the combination therapy significantly increase capillary density, promote restoration of perfusion in ischemic tissue, and improve limb salvage rate, compared with the transplantation of either gene-modified EPC alone. Being a convenient and objective method for noninvasive, repeated, and quantitative estimation for dermal blood flow, LDPI revealed profound differences in limb perfusion at day 21 after the induction of ischemia among different treatment groups.
EPC-based therapy, administered either systemically or locally, has shown promising results in numerous studies. 27 Genetically modified EPC has been considered useful in the design of strategies to achieve dual purposes: targeted delivery of therapeutic genes using EPC as vehicle and enhancement on the angiogenic properties of EPC by the expression of therapeutic genes.
VEGFA is the most abundant variant of the VEGF family. The reasons why we chose this VEGF isoform for transfection in our study were based on several unique properties of VEGFA: (1) VEGFA is essential for developmental angiogenesis because VEGFA deficient animals are embryonic lethal 28 ; (2) VEGFA is a hypoxia/glucose deprivation-inducible protein that characterizes VEGFA vs other members of the VEGF family and is upregulated in tissues with insufficient perfusion 29 ; and (3) VEGFA is Whole cell extracts were subjected to Western blotting, testing protein expression of VEGFA, and HO-1. The representative image of three independent experiments was shown (B, lower panel). *P < .001 vs pCMV-Tag 2B/empty vector control.
selective for vascular endothelium because its major tyrosine kinase receptors are selectively expressed on vascular endothelium. 30 Furthermore, our previous study 18 clearly demonstrated in experimental animal model that VEGFA-modified EPC could increase MVD, enhance perfusion in ischemic limb, and improve limb recovery rate, indicating that systemic administration of VEGFAmodified EPC remained as a reliable therapeutic approach for PAD.
Upregulation of stress-inducible antioxidant proteins such as HO-1 constitutes a defense system enabling tissue cells to cope with ischemia and reperfusion damage. 31 In our study, Q-PCR and Western blotting revealed that transplantation of HO-1-modified EPC led to the upregulation of VEGFA protein. This result was consistent with previous reports that overexpression of HO-1 mediated VEGF synthesis upon oxidative stress. 16 However, there was a considerable amount of skeletal muscle cells in our samples of ischemic tissue for Q-PCR or Western blotting. Skeletal muscle is also a rich source of VEGFA expression, especially upon ischemia. 32 Because of the anti-apoptotic property of HO-1 and its recently-revealed effect on Transgene expressions and microvessel density changes after transplantation. To test the efficiency of the transplantation of gene-modified endothelial progenitor cells (EPCs), six rats from each group were euthanized at day 7 after transplantation. Muscle tissue from ischemic limb was subjected to total RNA and protein extraction, as described in the Methods section. Total RNA was amplified by real-time polymerase chain reaction (RT-PCR) using specific vascular endothelial growth factor A (VEGFA), heme oxygenase-1 (HO-1), and b-actin primers. Data were expressed as the mean 6 standard deviation of six samples from each group (A, upper panel). Total protein was subjected to Western blotting, testing protein expressions of VEGFA and HO-1. The representative image of six blots was shown (A, lower panel). Microvessel density (MVD) was calculated as described in the Methods section at days 7, 14, and 21 after surgery (six rats from each group at each timepoint). Data were expressed as the mean 6 standard deviation capillaries/m 2 (B). MVD changes were compared among different time points in the same treatment group (B, left panel), and among different treatment groups at the same time point (B, right panel). *P < .05 vs phosphate-buffered saline (PBS); **P < .05 vs PBS or EPC; ***P < .001 vs PBS, EPC, VEGF, or HO-1. myocyte regeneration, the expression of VEGFA protein is probably the combined effect of increased VEGFA synthesis in HO-1-modified EPC and less apoptotic skeletal muscle cells. In our study, we conducted transplantation of both VEGFA-and HO-1-modified EPC, and demonstrated, for the first time, a cooperative role of both VEGF and HO-1 to promote neovascularization.
Similar with other studies associated with therapeutic use of EPCs, major hurdles such as cell senescence or phenotypic change during in vitro expansion, unclear development stage and purity of EPC even positive for certain markers of epithelial lineage, lack of targeted delivery, and uncontrolled expressions of exogenous genes remained in our research. In addition, there are several limitations that need to be addressed regarding our study. First, we are not able to answer the question whether the synergistic effect of HO-1 observed in this study was based on its anti-oxidant property or its angiogenic property.
Second, VEGF exerts various biologic effects through activating different pathways by binding to specific receptor tyrosine kinases. For example, the activation of PI3K/Akt pathway or the upregulation of antiapoptotic proteins (eg, B-cell lymphoma 2 [Bcl-2], X-linked inhibitor of apoptosis protein [XIAP], or survivin) were reported to mediate the pro-survival activity of VEGF. 33 HO-1 exerts its antiinflammatory or antioxidant effects partially through its products CO and biliverdin/bilirubin. The proangiogenic mechanism of HO-1, though not fully understood, is probably through the key angiogenic factors, including VEGF, SDF-1, and the recruitment of EPC to sites of vascular Recovery of perfusion and salvage rate of ischemic limbs after transplantation. Subcutaneous blood flow rate was detected by laser Doppler imager (LDPI). Calculated perfusion was expressed as the percentage ratio of average blood flow in the surgical limb to that in the healthy limb. Data were expressed as the (mean 6 standard deviation)% of six samples of each group (A). *P < .001 vs phosphate-buffered saline (PBS); **P < .05 vs PBS or endothelial progenitor cell (EPC); ***P < .001 vs PBS, EPC, vascular endothelial growth factor (VEGF), or heme oxygenase-1 (HO-1). The representative LDPI image set of 18 sets of images with similar results, taken from 18 animals at day 21 after surgery, was shown (B). The degree of ischemic damage in the affected limb evaluated macroscopically was shown (C). injury. 34 In this study, we did not evaluate the alterations of the downstream pathways or mediators under coexpression of VEGFA and HO-1.
It is our goal to be able to reveal the detailed molecular mechanism underlying the synergistic angiogenesis by VEGFA-and HO-1-modified EPCs in a future study.
CONCLUSIONS
We have shown for the first time in rat hindlimb ischemia model that VEGFA-modified EPC and HO-1-modified EPC synergized with each other in promoting angiogenesis. The hindlimb ischemia model with LDPI analysis is an excellent system for assessing candidates of gene-or cell-based revascularization therapeutics. In addition to VEGF, the introduction of HO-1 in EPC-based transplantation may serve as a novel and useful therapeutic strategy for ischemic disease of lower extremity. 
SUPPLEMENTARY METHODS (online only)
Western blotting detection of VEGF-R2, VEGF, and HO-1 protein. Cells were lysed in lysis buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM ethylenediaminetetraacetic acid, 0.5% Nonidet P-40, freshly added 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and 1Â protease inhibitor cocktail (Roche, Indianapolis, Ind). Ischemic muscle tissues were snapfrozen, grounded in liquid nitrogen and resolved in 2 ml of ice-cold buffer containing 20 mM Tris-HCl, pH 7.5, 10 mM b-glycerol phosphate, 2 mM sodium pyrophosphate, 1 mM ethylenediaminetetraacetic acid, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 1 g/mL leupeptin, and 1 mM dithiothreitol. The mixture was homogenized by sonication on ice. Equal amount of protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequent transfer to polyvinylidene fluoride membrane. Blots were incubated overnight at 4 C with rabbit polyclonal antibody against rat VEGF-R2 (sc-315; Santa Cruz, Dallas, Tex), VEGF (clone 147, sc-507; Santa Cruz), and HO-1 (clone H-105, sc-10789; Santa Cruz), followed by the incubation of horseradish peroxidase conjugated secondary antibodies (Pierce, Rockford, Ill) and chemiluminescent detection (Roche).
RNA extraction and real-time Q-PCR. Total RNA was extracted from cells or tissues using Trizol reagent (Invitrogen). For Q-PCR, 1 mg of DNase-treated total RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen), and PCR amplification was performed on an ABI PRISM 7700 sequence detection system (Applied Biosystems, Carlsbad, Calif) using SYBR green I dye (#4309155; Applied Biosystems) assay chemistry. The cycling conditions were as follows: (1) EPCs crawling microscopic slides of logarithmic growth were collected and fixed with 4% paraformaldehyde for 30 minutes, followed by PBS washing. IHC detection was achieved using anti-Rabbit/Mouse Poly-HRP IHC Detection Kit (2774; Millipore, Billerica, Mass). Rabbit polyclonal CD34 antibody (250591; Abbiotec, San Diego, Calf; 1:100), CD133 antibody (C9493; Sigma, 1:100), and vWF antibody (251228; Abbiotec; 1:100) were used as primary antibodies. After incubation with anti-Rabbit Poly-HRP, slides were incubated with freshly prepared DAB chromogen-buffer solution, followed by hematoxylin nuclear counterstaining. Negative control slides were run without primary antibody.
Rat hindlimb ischemia model establishment. 1 Briefly, a skin incision was performed on the medial aspect of the indexed thigh. The femoral artery was ligated and cut immediately distal to the inguinal ligament and proximal to the popliteal bifurcation site. No branches were ligated along the length of the excised segment.
